Dendritic cell-based cancer immunotherapy targeting MUC-1.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 63, doi. 10.1007/s00262-005-0673-6
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2006 AND VI 55 AND IP 1
Results: 14
1
2
Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 76, doi. 10.1007/s00262-005-0676-3
- By:
- Publication type:
- Article
3
Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 47, doi. 10.1007/s00262-005-0704-3
- By:
- Publication type:
- Article
4
Development of a whole cell vaccine for acute myeloid leukaemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 68, doi. 10.1007/s00262-005-0674-5
- By:
- Publication type:
- Article
5
Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 31, doi. 10.1007/s00262-005-0690-5
- By:
- Publication type:
- Article
6
Adoptive T cell therapy of solid cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 96, doi. 10.1007/s00262-005-0706-1
- By:
- Publication type:
- Article
7
Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 39, doi. 10.1007/s00262-005-0700-7
- By:
- Publication type:
- Article
8
Immunogenic HER-2/neu peptides as tumor vaccines.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 85, doi. 10.1007/s00262-005-0692-3
- By:
- Publication type:
- Article
9
Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 23, doi. 10.1007/s00262-005-0688-z
- By:
- Publication type:
- Article
10
Immunotherapeutic potential of DISC-HSV and OX40L in cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 104, doi. 10.1007/s00262-005-0004-y
- By:
- Publication type:
- Article
11
Progress in vaccination against cancer 4.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 61, doi. 10.1007/s00262-005-0033-6
- By:
- Publication type:
- Article
12
Characterization of glycosylation and adherent properties of melanoma cell lines.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 112, doi. 10.1007/s00262-005-0019-4
- By:
- Publication type:
- Article
13
Mouse models of efficient and inefficient anti-tumor immunity, with emphasis on minimal residual disease and tumor escape.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 1, doi. 10.1007/s00262-005-0007-8
- By:
- Publication type:
- Article
14
Tripeptide tyroserleutide enhances the antitumor effects of macrophages and stimulates macrophage secretion of IL-1β, TNF-α, and NO in vitro.
- Published in:
- Cancer Immunology, Immunotherapy, 2006, v. 55, n. 1, p. 56, doi. 10.1007/s00262-005-0024-7
- By:
- Publication type:
- Article